{"id":"NCT02668653","sponsor":"Daiichi Sankyo","briefTitle":"Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)","officialTitle":"A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (QuANTUM First)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-09-01","primaryCompletion":"2021-08-13","completion":"2023-06-16","firstPosted":"2016-01-29","resultsPosted":"2022-10-05","lastUpdate":"2024-08-06"},"enrollment":539,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Acute Myeloid Leukemia","Leukemia"],"interventions":[{"type":"DRUG","name":"Chemotherapy","otherNames":["Cytarabine","Daunorubicin","Idarubicin"]},{"type":"DRUG","name":"Quizartinib","otherNames":["Test Product"]},{"type":"DRUG","name":"Placebo","otherNames":["Placebo Control"]}],"arms":[{"label":"Chemotherapy plus quizartinib","type":"EXPERIMENTAL"},{"label":"Chemotherapy plus placebo","type":"ACTIVE_COMPARATOR"}],"summary":"Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research.\n\nAdults might be able to join this study after bone marrow tests show they have a certain kind of blood cancer (FLT3-ITD AML).\n\nParticipants will have an equal chance of receiving quizartinib or placebo along with their chemotherapy.","primaryOutcome":{"measure":"Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia","timeFrame":"Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment","effectByArm":[{"arm":"Quizartinib","deltaMin":31.9,"sd":null},{"arm":"Placebo","deltaMin":15.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0324"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":244,"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","China","Croatia","Czechia","France","Germany","Hong Kong","Hungary","Israel","Italy","Japan","Poland","Portugal","Romania","Russia","Serbia","Singapore","South Korea","Spain","Taiwan","Ukraine","United Kingdom"]},"refs":{"pmids":["40079105","37116523","29859851"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":146,"n":265},"commonTop":["Pyrexia","Febrile neutropenia","Diarrhoea","Hypokalaemia","Nausea"]}}